glp-1/glp-2 dual agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data The mechanisms of dual incretin
Description
Apply a new patch daily
Rondas, D., DHertog, W., Overbergh, L
Structure of the glucagon receptor in complex with a glucagon analogue
46 KahleM.SchferA.SeeligA.SchultheiJ.WuM.AichlerM.et al (2015)
Most agents undergo proteolytic degradation and renal elimination
The dose-response analysis determined an ED of 242.9 mg/kg and a maximum efficacy (E max ) of 54%, based on 1-h post-administration values [71]
